All In Biotech

Free tool

Drugs in development

Investigational drugs and biologics in industry-sponsored Phase 2 and Phase 3 trials that are active or finished in the last two years, and that FDA has not approved. Built from 10,322 ClinicalTrials.gov records, with code names and generic names merged. For approved drugs, use Drug Search.

Last checked: Nov 20, 2026Latest source record: rebuilt Nov 18, 2026Source: ClinicalTrials.govMethods & limitations

Drugs in development

3,685

Not FDA-approved

In Phase 3

1,424

Highest phase reached

Matching your filters

111

Reset

111 drugs in development

Names, sponsors and conditions come from the trial records. Click a drug for its trials.

  • BMS-986368CC-97489Phase 22 trials

    Bristol Myers Squibb · Agitation, Alzheimer Disease, Multiple Sclerosis Spasticity

  • BPL-003Phase 22 trials

    Beckley Psytech Limited · Treatment Resistant Depression

  • DT-101Phase 22 trials

    Draig Therapeutics Ltd · Major Depressive Disorder (MDD)

  • IcalcaprantABBV-1354, CVL-354Phase 22 trials

    AbbVie · Bipolar I Disorder, Bipolar II Disorder, Major Depressive Disorder

  • ONO-2020Phase 22 trials

    Ono Pharmaceutical Co., Ltd. · Agitation Associated With Alzheimer's Disease Dementia, Alzheimer Disease

  • PEX010-Assisted TherapyPEX010Phase 22 trials

    Filament Health Corp. · Stimulant Use Disorder, Opioid Use Disorder

  • SPT-300LYT-300, GlyphAlloPhase 22 trials

    Seaport Therapeutics · Major Depressive Disorder (MDD), Major Depressive Disorder With Anxious Distress

  • SunobinopV117957Phase 22 trials

    Knoa Pharma LLC · Alcohol Use Disorder

  • ZelquistinelGATE-251Phase 22 trials

    Syndeio Biosciences, Inc · Major Depressive Disorder

  • ACP-211Phase 21 trial

    ACADIA Pharmaceuticals Inc. · Major Depressive Disorder (MDD), Depressive Disorder, Treatment-Resistant

  • ALKS 7290Phase 21 trial

    Alkermes, Inc. · Attention Deficit Disorder With Hyperactivity (ADHD)

  • ALTO-100Phase 21 trial

    Alto Neuroscience · Bipolar Disorder I or II With a Major Depressive Episode

  • ALTO-101Phase 21 trial

    Alto Neuroscience · Schizophrenia, Cognitive Impairment

  • ALTO-203Phase 21 trial

    Alto Neuroscience · Major Depressive Disorder, Anhedonia

  • ALTO-207Phase 21 trial

    Alto Neuroscience · Treatment-resistant Depression (TRD)

  • ALTO-300Phase 21 trial

    Alto Neuroscience · Major Depressive Disorder

  • BMS-986511EvifacotrepPhase 21 trial

    Bristol Myers Squibb · Major Depressive Disorder

  • BR5402APhase 21 trial

    Boryung Pharmaceutical Co., Ltd · Schizophrenia

  • BR5402A-1Phase 21 trial

    Boryung Pharmaceutical Co., Ltd · Schizophrenia

  • BR5402BPhase 21 trial

    Boryung Pharmaceutical Co., Ltd · Schizophrenia

  • BR5402B-1Phase 21 trial

    Boryung Pharmaceutical Co., Ltd · Schizophrenia

  • BR5402CPhase 21 trial

    Boryung Pharmaceutical Co., Ltd · Schizophrenia

  • BR5402C-1Phase 21 trial

    Boryung Pharmaceutical Co., Ltd · Schizophrenia

  • BR5402DPhase 21 trial

    Boryung Pharmaceutical Co., Ltd · Schizophrenia

  • BR5402D-1Phase 21 trial

    Boryung Pharmaceutical Co., Ltd · Schizophrenia

  • CLE-100Phase 21 trial

    Clexio Biosciences Ltd. · Adjunctive Treatment of Major Depressive Disorder (MDD)

  • CMND-100MEAIPhase 21 trial

    Clearmind Medicine Inc. · Alcohol Use Disorder

  • CYB004Phase 21 trial

    Cybin IRL Limited · Generalized Anxiety Disorder

  • ELE-101Phase 21 trial

    Eleusis Therapeutics · Healthy Volunteers, Major Depressive Disorder, Depression

  • EMP-01Phase 21 trial

    atai Therapeutics, Inc. · Social Anxiety Disorder

  • ENA-001Phase 21 trial

    Enalare Therapeutics Inc. · Respiratory Depression

  • GM-1020Phase 21 trial

    Gilgamesh Pharmaceuticals · Major Depressive Disorder

  • GM-2505Phase 21 trial

    AbbVie · Major Depressive Disorder

  • GXV813Phase 21 trial

    Novartis · Schizophrenia

  • INDV-2000Phase 21 trial

    Indivior Inc. · Opioid Use Disorder

  • INDV-6001Phase 21 trial

    Indivior Inc. · Moderate to Severe Opioid Use Disorder

  • JNJ-89495120Phase 21 trial

    Johnson & Johnson (Janssen) · Depressive Disorder, Major

  • KYN-5356Phase 21 trial

    Kynexis B.V. · Cognitive Impairment Associated With Schizophrenia (CIAS)

  • LY03020Phase 21 trial

    Luye Pharma Group Ltd. · Schizophrenia

  • MT1988Phase 21 trial

    Monument Therapeutics Limited · Clinical High Risk for Psychosis (CHR)

  • NBI-1070770Phase 21 trial

    Neurocrine Biosciences · Major Depressive Disorder

  • NBI-1117570Phase 21 trial

    Neurocrine Biosciences · Schizophrenia

  • NH102Phase 21 trial

    Jiangsu Nhwa Pharmaceutical Co., Ltd. · Major Depressive Disorder (MDD)

  • NORA520Phase 21 trial

    TWi Biotechnology, Inc. · Depression, Postpartum, Postpartum Depression, Post-partum Depression

  • NS-136Phase 21 trial

    NeuShen Therapeutics · Schizophrenia(Acute)

  • NTX-1472Phase 21 trial

    Newleos Therapeutics, Inc. · Social Anxiety Disorder (SAD)

  • NV-5138SPN820Phase 21 trial

    Navitor Pharmaceuticals, Inc. · Treatment Resistant Depression

  • PDC-1421Phase 21 trial

    BioLite, Inc. · Major Depressive Disorder

  • PRT042Phase 21 trial

    Sichuan Purity Pharmaceutical Technology Co., Ltd. · Major Depressive Disorder (MDD

  • RE03Phase 21 trial

    Reconnect Labs · Posttraumatic Stress Disorder (PTSD), Sleep Disturbances and Insomnia

NewerPage 2 of 3Older

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.